First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
english health business
First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA[2] study which recently... 2026-07-15 20:30:00
Dernières nouvelles et titres
First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hos...
Nouvelles